Search

Coronavirus Disease 2019 (COVID-19) is affecting millions of people globally. Several neutralizing monoclonal antibodies have been developed to limit the progression and complications of the disease. These treatments provide immediate and passive immunity. The combination therapy with Bamlanivimab plus Etesevimab led to a lower incidence of COVID-19-related hospitalization and death and a faster reduction in the SARS-CoV-2 viral load. No or rare cases of cardiovascular side effects are reported. We present the case of a high-risk 79-years-old woman who developed atrial fibrillation with aberrant ventricular conduction after administration of neutralizing monoclonal-antibodies Bamlanivimab plus Etesevimab. The woman with a history of insulin-dependent diabetes and Grade II follicular Non-Hodgkin Lymphoma previously vaccinated with two doses of Pfizer COVID-19 vaccine, presented with malaise, headache, and SARS-CoV-2 nasal swab reverse transcription-polymerase chain reaction tested positive for the infection. She received a single dose of Bamlanivimab (70 mg) + Etesevimab (1400 mg). After about a week, she developed atrial fibrillation with uncontrolled response to frequent premature ventricular complexes and aberrant ventricular conduction. This case presents a high-risk woman with SARS-CoV-2 infection who developed a serious adverse cardiovascular event some days after receiving neutralizing monoclonal antibodies. Risk factors including sex, age, anxiety related to isolation and infection, and COVID-19 itself may have all contributed to atrial fibrillation. Arrhythmia may rarely occur after monoclonal-antibodies treatment, although recommended timing to monitor patients is from 1 to 24 h after the administration of these antibodies. Appreciation of this potential association is important for evaluating monoclonal-antibody treatments' safety and optimizing patient monitoring and follow-up.

Introduction: The study aims to evaluate the seasonal variation of out-of hospital cardiac arrest (OHCA) in a tourist-intensive area., Methods: Data of all OHCA treated by the Emergency Medical Service of Lecce (LE-EMS), Italy, between 2013 and 2017, were retrospectively analyzed and complemented with information about tourist flows, in order to determine the influence of the seasonal variation of population on incidence and outcome., Results: Tourist arrivals were around 1,700,000 per year, mostly in summer, adding up to 803,161 residents. The occurrence of OHCA did not show a monthly variation when referring to the resident population (p = 0.90). When taking into account the tourist flows, a difference in occurrence of OHCA across months was found, with the highest rate of arrests in December and the lowest in August (10.3 vs 3.4 per 100,000 persons, p < 0.01). No difference was found in terms of EMS arrival time and event survival rate between summer and the rest of the year (13.6 vs 13.8 min, p = 0.55, and 4.4% vs 4.5%, p = 0.86, respectively)., Conclusion: In summer tourism areas, the occurrence of OHCA is unchanged throughout the year, while the actual population presents seasonal increases. Summer enhancement of provincial EMS may contribute to maintain the performance of emergency care., (Copyright © 2020 Elsevier Ltd. All rights reserved.)

The occurrence of hypophosphatemia after iron infusion has been known for a long time but has only recently led to clinical concerns. It was considered to be of low clinical importance. The elucidation of the physiological mechanisms responsible for this effect, involving FGF23 and the ever-increasing number of cases with regard to the potentially very serious consequences on bone metabolism have recently raised probably justified concerns. In this article, we summarize the mechanisms of phosphate homeostasis, how intravenous iron can induce a phosphate deficiency and what precautions and treatments needs to be undertaken to prevent it., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.